Neurological disease model

Details Neurological disease model Neurological disease model

1999-03-08

2003-05-20

Baker, Anne-Marie (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Method of using a transgenic nonhuman animal in an in vivo...

C800S013000, C800S014000, C800S018000, C800S008000, C800S009000

Reexamination Certificate

active

06566580

ABSTRACT:

This is a national stage of International Application Ser. No. PCT/EP97/04985, filed Sep. 11, 1997.
The present invention relates to metabotropic glutamate receptors (mGluRs). In particular, the invention relates to the mGlu
7
receptor and novel applications thereof in models for neurological disease and as a target for neuroactive drugs.
L-glutamate is the major excitatory neurotransmitter in the central nervous system (CNS). Two major classes of glutamatergic receptors exist. The first class, the ionotropic receptors, which consists of NMDA, AMPA and kainate receptors, is responsible for fast synaptic transmission in the mammalian CNS. The second class, the metabotropic glutamate receptors (mGluR), exert actions on neurotransmission, synaptic plasticity and cellular excitation that are less well characterised.
Synaptic release of neurotransmitter in the nervous system is often influenced by presynaptic mGluRs which in turn respond to neurotransmitters released from the same nerve terminal or from terminals of other neurons. The mGluRs have diverse critical roles in forms of synaptic plasticity such as long term potentiation (LTP) or long term depression, forms of synaptic plasticity believed to be involved in learning and memory in vertebrates. Presynaptic mGluR autoreceptors respond to glutamate and influence the probability of neurotransmitter release from a nerve terminal. In general, the activation of presynaptic mGluRs (e.g. class III mGluRs activated by L-AP4), has been found to reduce transmitter release from synapses in many brain regions.
One member of the mGluR family, mGluR7, has been only poorly characterised to date. It is the most conserved member of the mGluR family, with only 6-8 amino acid differences observed between rat and human proteins. mGluR7 is widely distributed throughout the nervous system and is localised presynaptically close to neurotransmitter release sites. In the hippocampus, a high density of the mGlu
7
a isoform (note: to date only two isoforms of mGluR7, a and b, that differ only in their carboxy-terminal amino acid sequence have been characterized; Flor, P. J., van der Putten, H., Ruegg, D., Lukic, S., Leonhardt, T., Sansig, G., Knoepfel, T., and Kuhn, R. 1996. A novel splice variant of a metabotropic glutamate receptor, human mGluR7b;
Neuropharmacology
36, 153-159) is found, in particular, in presynaptic terminals of excitatory cells that synapse on mGluR1&agr; expressing GABA-ergic interneurons that also express somatostatin. Therefore, the input of this particular class of interneuron seems to be endowed by a particularly strong mGluR7-mediated autoregulation. Why this is so remains speculative for the moment and it has been suggested that this peculiar mGluR7-mediated autoregulation might relate to the role of the mGluR1&agr;
1
-positive interneurons in the hippocampal network (Shigemoto et al., Nature (1996) 318:523-525). mGluR1&agr;
+
cells receive glutamatergic input from axon collaterals of principal cells. The GABAergic terminals of mGluR1&agr;
+
cells make synapses on principal cell distal dendrites, which also receive a direct excitatory input from the entorhinal cortex.
It has been hitherto generally accepted and shown that the glutamate analogue (S)-2-amino-4-phosphonobutanoate (L-AP4) induced presynaptic suppression of neurotransmitter release. In several instances, it has been proposed that such an effect could be mediated by activation of mGluR7 receptors. In other words, it has been proposed that activation of mGluR7 results in inhibition of neurotransmitter release. Building on this presumption, Shigemoto et al. (Op. Cit.) suggest that the high level of presynaptic mGluR7 may suppress the release of glutamate when action potentials arrive at high frequency, allowing glutamate release to follow only relatively low frequency synaptic firing. According to this hypothesis mGluR7 would work as a low pass filter and its gating function would allow low but not high frequency stimuli to be passed on effectively. This has implications for the use of glutamate agonists and/or antagonists in the therapy of disorders associated with synaptic plasticity, such as learning and memory disorders, epilepsy, pain and possibly ischaemia. According to the generally accepted model, a mGluR7 agonist would be effective in reducing transmitter release and a mGluR7 agonist would have more pronounced-effects on transmitter release in terminals that are particularly enriched in mGluR7 such as excitatory terminals onto mGluR1&agr;
+
interneurons. Also, according to data and models proposed, so far, agonists of mGluR7 would have more pronounced inhibitory effects on excitatory terminals that release transmitter to interneurons. This would favour a decrease in inhibition exerted by the interneurons. Agonists of mGluR7 might therefore lower rather than enhance thresholds for seizures and epilepsy caused by decreased inhibition. Current models thus favour the development of antagonists rather than agonists of mGluR7 for the treatment of diseases such as epilepsy or relieving symptoms related to a reduction of neurotransmitter release.
We have used knockout mice in which the mGluR7 gene has been deleted in order to determine that this hypothesis and its implications are incorrect. mGluR7 facilitates rather than inhibiting glutamate release.
SUMMARY OF THE INVENTION
The present invention provides the use of a metabotropic glutamate receptor mGluR7 agonist for the facilitation of neurotransmitter release from a nerve ending. Moreover, the invention.provides transgenic knockout non-human mammals lacking the mGluR7 gene, suitable for studying mGluR7 and modulators thereof. Furthermore, the transgenic knockout mammals according to the invention are suitable for the study of epilepsy.


REFERENCES:
patent: 95/08627 (1995-03-01), None
patent: 95 18154 (1995-07-01), None
F Shalaby et al., Nature, “Failure of blood-island formation anf vasculogenesis in Flk-1-deficient mice,” Jul. 1995, vol. 376, pp. 62-70.*
CD Sigmund, Arterioscler Thromb Vasc Biol., “Viewpoint: Are Studies in Genetically Altered Mice Out of Control!” 2000, 20:1425-1429.*
CB Moena, Development, “Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus,” 1991,pp. 485-499.*
K.H.S. Campbell et al., Theriogenology,“Totipotency or multiipotentiality of cultured cells: Applications and Progress,”Jan. 1997, vol. 47, Issue 1, pp. 63-72.*
A. Bradley et al., Bio/Technology, “Modifying the mouse:Design and desire,” May 1992, vol. 10, pp. 534-539.*
W. French Anderson. Human gene therapy. Nature, vol. 392, pp. 25-30. 1998.*
Ilyin et al. Pharmacology of ACEA-1416: a potent systemically actice NMDA receptor glycine site antagonist. European Journal of Pharmacology. vol. 310, pp. 107-114. 1996.*
Tizzano et al. Induction of protection of limbic seizures in mice by mGluR subtype selective agonists. Neuropharmacology. vol. 34, No. 8, pp. 1063-1067. 1995.*
F. Conquet. Inactivation in vivo of metabotropic glutamate receptor 1 by specific chromosomal insertion of reporter gene lacZ. Neuropharmacology. vol. 34, No. 8, pp. 865-870. 1995.*
Ronald G. Crystal. Transfer of genes to humans: early lessons and obstacles to success. Science, vol. 270, pp. 404-410, 1995.*
Suzuki et al. Anticonvulsant action of metabotropic glutamate receptor agonists in kindled amygdala of rats. Neuroscience Letters, vol. 204, pp. 41-44, 1996.*
Tizzano et al. Intracerebral 1s, 3R-1 aminocyclopentane-1,3-dicarboxylic acid(1s,3R-acpd) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists. Neuroscience Lett. 162, 12-16, 1993.*
Brandstätter et al., Journal of Neuroscience, vol. 16(15), “Compartmental Localization of Metabotropic Glutamate Receptor (mGluR7): Two Different Active Sites at a Retinal Synapse,” pp. 4749-4756 (1996).
Capecchi M.R., Science, vol. 244, “Altering the Genome by Homologous Recombination,” pp. 1288-1292 (1989).
Conquet F., Neuropharmacology, vol. 34(8), “Inactivation In Vivo of Metabotropic Glutamate R

Affiliated with

Also associated with

Rating

Neurological disease model does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neurological disease model, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurological disease model will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3018983